



**HAL**  
open science

## Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen

David Haines, Balazs Varga, Istvan Bak, Bela Juhasz, Fadia Fouad Mahmoud, Hejbatullah Kalantari, Rudolf Gesztelyi, Istvan Lekli, Attila Czompa, Arpad Tosaki

### ► To cite this version:

David Haines, Balazs Varga, Istvan Bak, Bela Juhasz, Fadia Fouad Mahmoud, et al.. Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen. *Phytotherapy Research*, Wiley, 2010, 25 (1), pp.128. 10.1002/ptr.3160 . hal-00599826

**HAL Id: hal-00599826**

**<https://hal.archives-ouvertes.fr/hal-00599826>**

Submitted on 11 Jun 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Summative Interaction Between Astaxanthin, Ginkgo biloba Extract (EGb761) and Vitamin C in Suppression of Respiratory Inflammation: A comparison with Ibuprofen**

Journal:	<i>Phytotherapy Research</i>
Manuscript ID:	PTR-09-0458.R3
Wiley - Manuscript type:	Full Paper
Date Submitted by the Author:	12-Feb-2010
Complete List of Authors:	Haines, David; University of Connecticut, Molecular & Cell Biology Varga, Balazs; University of Debrecen, Pharmacology Bak, Istvan; University of Debrecen, Pharmacology Juhasz, Bela; University of Debrecen, Pharmacology Mahmoud, Fadia; Kuwait University, Medical Laboratory Sciences Kalantari, Hejbatullah; Ahvaz Jundishapur University of Medical Sciences, Pharmacology and Toxicology Gesztelyi, Rudolf; University of Debrecen, Pharmacology Lekli, Istvan; University of Debrecen, Pharmacology Czompa, Attila; University of Debrecen, Pharmacology Tosaki, Arpad; University of Debrecen, Pharmacology
Keyword:	Inflammation, Ibuprofen, Astaxanthin, Ginkgolide, cAMP, cGMP



1  
2  
3 **Summative Interaction Between Astaxanthin, *Ginkgo biloba* Extract (EGb761) and**  
4 **Vitamin C in Suppression of Respiratory Inflammation: A Comparison with**  
5 **Ibuprofen**  
6  
7

8 **David D. Haines<sup>1,2</sup>, Balazs Varga<sup>1</sup>, Istvan Bak<sup>1</sup>, Bela Juhasz<sup>1</sup>, Fadia F. Mahmoud<sup>3</sup>,**  
9 **Hejbatullah Kalantari<sup>4</sup>, Rudolf Gesztelyi<sup>1</sup>, Istvan Lekli<sup>1</sup>, Attila Czompa<sup>1</sup>, Arpad**  
10 **Tosaki<sup>1</sup>**  
11

12 <sup>1</sup>*Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen,*  
13 *Hungary*  
14

15 <sup>2</sup>*Department of Molecular and Cell Biology, University of Connecticut, Storrs CT USA*  
16

17 <sup>3</sup>*Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait*  
18 *University, Kuwait*  
19

20 <sup>4</sup>*School of Pharmacy, Department of Pharmacology and Toxicology, Ahvaz Jundishapur*  
21 *University of Medical Sciences, Iran*  
22

23 **Short Title:** Phytochemicals cooperatively suppress inflammation.  
24  
25  
26

27 **Correspondence:**

28 Prof. Arpad Tosaki, Ph.D., D.Sc.  
29 Dept. Pharmacology, Medical Health Science Center  
30 Faculty of Pharmacy  
31 University of Debrecen  
32 Nagyerdei krt. 98  
33 4032-Debrecen  
34 Hungary  
35

36 TEL: +36-52-255-586,  
37 FAX: +36-52-255-586  
38 E-mail: [tosaki@king.pharmacol.dote.hu](mailto:tosaki@king.pharmacol.dote.hu)  
39  
40

41 **Sponsor's information:** This study was supported by grants from OTKA 72315, OTKA  
42 78223, GVOP-3.2.1.-2004-04-0269/3.0, TAMOP-4.2.2-08/1-2008-0007, and TAMOP-  
43 4.2.1.B-09/1  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

Here, combinations of *Ginkgo biloba* leaf extract (EGb761) plus the carotenoid antioxidant astaxanthin (ASX) and vitamin C are evaluated for summative dose effect in inhibition of asthma-associated inflammation in asthmatic Guinea Pigs. Ovalbumin-sensitized Hartley Guinea pigs challenged with ovalbumin aerosol to induce asthma, were administered EGb761, ASX, vitamin C, or ibuprofen. Following sacrifice, Bronchoalveolar lavage (BAL) fluid was evaluated for inflammatory cell infiltrates and lung tissue cyclic nucleotide content. Each parameter measured was significantly altered to a greater degree by drug combinations, than by each component acting independently. An optimal combination was identified that included astaxanthin (10 mg/kg), vitamin C (200 mg/kg), and EGb761 (10 mg/kg), resulting in counts of eosinophils and neutrophils each 1.6-fold lower; macrophages 1.8-fold lower, cAMP 1.4-fold higher; and cGMP 2.04-fold higher than levels in untreated, asthmatic animals ( $p < 0.05$ ). In conclusion, EGb761, ASX and vitamin C are shown here to interact summatively to suppress inflammation with efficacy equal to or better than ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID). Such combinations of non-toxic phytochemicals constitute powerful tools for prevention of onset of acute and chronic inflammatory disease if consumed regularly by healthy individuals; and may also augment effectiveness of therapy for those with established illness.

**Key words:** Inflammation, Astaxanthin, Ginkgolide, ibuprofen, cAMP, cGMP.

## INTRODUCTION

This report describes progress toward creation of dietary phytochemical formulations (“functional foods”) containing bioactive components that interact summatively to strengthen host immunoregulatory mechanisms which prevent inflammation from becoming pathological; and augment drug therapies for age-related illnesses such as arthritis, cardiovascular syndromes, dementia, autoimmunity and many other severe conditions with underlying inflammatory pathogenesis. The products are designed to mediate therapeutic and preventive clinical outcomes equivalently or superior to commonly-used non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, corticosteroids and other pharmaceuticals, but with negligible adverse effects and at low cost to patients. Beyond their medical use it is anticipated that such products may be consumed for general health as food supplements and additionally provide protection against debilitating effects of a diverse range of illness. Here the anti-inflammatory capacity of the NSAID ibuprofen is compared with formulations incorporating three naturally-occurring products: the dietary carotenoid astaxanthin (ASX), *Ginkgo biloba* whole leaf extract (EGb761) and vitamin C, for the ability to independently or interactively affect major indicators of inflammatory disease severity in ovalbumin-sensitized asthmatic guinea pigs.

Asthma was used as a disease model in this study, although this disorder was not our focus. Asthma pathogenesis is a cascade of progressively severe inflammatory processes initiated by an immune imbalance (Umetsu et al. 2002) and provides a very good general paradigm for severe chronic inflammation. Moreover, the commonality of

1  
2  
3 signaling pathways leading to tissue damage in asthma and most other inflammatory  
4 syndromes means that treatment strategies affecting major indicators of asthma-  
5 associated inflammation are likely to be relevant for many conditions in which  
6 inflammation plays an underlying role.  
7  
8  
9  
10  
11

12 The emphasis here on general inflammatory, rather than asthma-specific  
13 processes, led to the choice of ibuprofen for comparison with the other agents in the  
14 context of anti-inflammatory potency. Ibuprofen is a widely-used NSAID that acts by  
15 strong inhibition of cyclooxygenases (COX), enzymes which metabolize membrane  
16 phospholipids into mediators called prostanoids, small molecules regulating a diverse  
17 range of homeostatic functions including inflammation (Soberman and Christmas 2003).  
18 The drug acts on both major isoforms of the enzyme: COX-1 which is constitutively  
19 expressed in most cells and acts to protect tissues such as lining of small airways and the  
20 gastrointestinal tract (Chandrasekharan et al. 2002; Soberman and Christmas 2003;  
21 Warner and Mitchell 2002); and an inducible variant, COX-2, responsible for production  
22 of inflammatory mediators in macrophages, neutrophils and other cells participating in  
23 inflammation (Grosser 2009).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Ibuprofen has clinical utility in many diseases for which inflammation is a  
42 major component (Hawkey 2001; Wallace 1999) and therefore, serves as a valuable  
43 benchmark against which the therapeutic potential of other NSAIDs may be compared.  
44 However, unlike the phytochemical products used in these experiments, ibuprofen cannot  
45 be administered long-term as prophylaxis against inflammatory disease owing to its  
46 toxicity (Bjarnason 2007; Moore 2007). For this reason, formulations with anti-  
47 inflammatory potency in the same range as ibuprofen, but without adverse side effects,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 constitute extremely valuable prophylaxes and therapy for persons at-risk of, or  
4  
5 diagnosed with illness such as asthma, allergies, arthritis and other chronic inflammatory  
6  
7 conditions.  
8  
9

10  
11 Activation of many cell types during inflammation typically results in a cascade  
12  
13 of processes in which autocrine and paracrine expression of platelet activating factor  
14  
15 (PAF) is a major event. This molecule interacts with PAF receptors (PAFR) to cause  
16  
17 release of cytosolic calcium from cellular stores, constituting a positive feedback process  
18  
19 that amplifies immune cell activation and the severity of associated inflammatory  
20  
21 pathologies (Asako et al. 1992; Sasakawa et al. 2000; Wenzel-Seifert and Seifert 1993).  
22  
23 Compounds in Ginkgo extract (ginkgolides) that block PAFR thereby inhibiting increases  
24  
25 of intracellular calcium, interrupt this process (Brochet et al. 1999), thereby allowing  
26  
27 lower doses of drug to suppress calcium-dependent activation events resulting in  
28  
29 enhanced therapeutic outcomes (Bagnis et al. 1996; Brochet et al. 1999; Haines et al.  
30  
31 2000).  
32  
33  
34  
35

36  
37 The present investigation builds on previous work by the authors demonstrating  
38  
39 synergism between EGb761 and the immunosuppressant FK506 in an *ex vivo* rat heart  
40  
41 model (Haines et al. 2000); and between ASX and Ginkgolide B (GB) a purified, PAFR-  
42  
43 inhibitory ginkgolide, in a cultured human peripheral blood mononuclear cell (PBMC)  
44  
45 model (Mahmoud et al. 2002; Mahmoud et al. 2004). Neither ASX nor EGb761 are  
46  
47 independently potent enough to be used as stand-alone treatment of serious inflammatory  
48  
49 disease. However, it is here hypothesized that both compounds summate when co-  
50  
51 administered, to mediate therapeutic effects in the same range as currently available  
52  
53 single-molecule drugs, with ibuprofen used in these experiments as a comparative model.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The therapeutic effects of ginkgolides are due substantially to their ability to block PAF-PAFR-dependent calcium signaling, leading to prevention of inflammatory tissue damage (Bagnis et al. 1996; Brochet et al. 1999). ASX-mediated cytoprotection occurs through a different mechanism, involving highly efficient scavenging of toxic reactive oxygen compounds by ASX, with the additional capacity to induce host antioxidant defenses (Kang, Kim, and Kim 2001; Wang, Willen, and Wadstrom 2000). The biological action of both ginkgolides and ASX result in several common anti-inflammatory effects, including down-regulation of potentially pathological T cell activity (Mahmoud et al. 2002; Mahmoud et al. 2004). Thus, ginkgolides and ASX potentially exhibit additive and possibly synergistic interaction, an outcome seen in many drug combinations that act via different physiological pathways resulting in therapeutic benefits greater than that of each drug acting independently (Evans 2003; Haines et al. 2000; Mahmoud et al. 2002; Mahmoud et al. 2004).

## MATERIALS AND METHODS

### *Animals (ethical background and institutional policy):*

Male Hartley guinea pigs weighing between 250-350 grams and kept under pathogen-free conditions were used for all experiments in this study. Animals were maintained at the Animal Care facility at the School of Pharmacy, University of Debrecen, in Debrecen, Hungary. All activities in this study involving animal transport, care, experimentation and sacrifice have been reviewed and confirmed by University of Debrecen's committee for animal experiments. Standards of animal use demanded by this committee include an experimental design conducted on a valid scientific and ethical



1  
2  
3 basis, with particular attention given to animal welfare. Animal use protocols at this  
4  
5 institution emphasize respect and humane treatment of experimental animals, to include  
6  
7 three main principles: (i) Minimization of stress and discomfort (ii) Conduct non-animal  
8  
9 experiments where possible; and (iii) Minimization of the number of animals used to  
10  
11 statistically valid sample sizes.  
12  
13  
14  
15  
16

17  
18 *Drug administration and treatment groups:*  
19

20  
21 Pharmacological agents used for this investigation include *Ginkgo biloba* whole  
22  
23 leaf extract (EGb761), astaxanthin (ASX), vitamin C (Natural Alternatives International  
24  
25 Inc., San Marcos California, USA) and ibuprofen (Abbott Laboratories, Abbott Park  
26  
27 Illinois, USA) – hereafter for the purpose of brevity referred to as “drugs”. Drugs were  
28  
29 given orally with feed to groups of 6 animals, segregated on the basis of dosage and type  
30  
31 of drug. Five studies were conducted, each defined by administration of a particular drug.  
32  
33 The treatment groups included animals fed: (1) astaxanthin; (2) ginkgo extract/EGb761;  
34  
35 (3) vitamin C; (4) combinations of the previous 3 agents; and (5) ibuprofen. Controls  
36  
37 included one drug-free, non-asthmatic control group; and one drug-free asthmatic cohort.  
38  
39 Animals in both control groups were OA-sensitized and given the same feed vehicle as  
40  
41 treatment groups, but non-drug supplemented. One of these was subsequently challenged  
42  
43 with inhaled OA to induce an asthmatic response. The second received no OA challenge  
44  
45 and remained asthma free.  
46  
47  
48  
49

50  
51 In initial studies of the effect of each agent on asthma-associated disease  
52  
53 indicators, independent of the action of the other drugs, guinea pigs were administered a  
54  
55 daily regimen of 5-200 mg astaxanthin per kg body weight; 5-100 mg/kg of ginkgo  
56  
57  
58  
59  
60

1  
2  
3 extract; 50-400 mg/kg vitamin C; and various combined dosages of astaxanthin, ginkgo  
4  
5 and vitamin C. Each drug was dispersed into a suspension of 1% methylcellulose in  
6  
7 physiological saline, which was then added to standard rodent chow. Drug treatments for  
8  
9 each study covered a time period of 26 days and ran concurrently with allergen  
10  
11 sensitization (see asthmatic response induction protocol below). Animals were monitored  
12  
13 throughout the 26 day preconditioning period for any signs of adverse reaction to  
14  
15 treatments with special attention being given to unexplained death, tremors, agitation,  
16  
17 breathing difficulties, lethargy random body movements or spasms, and precipitous gain  
18  
19 or loss of weight.  
20  
21  
22  
23

#### 24 25 26 27 *Induction of Asthmatic response:*

28  
29 Asthmatic responses were induced in animals by sensitization to ovalbumin (OA)  
30  
31 and subsequent aerosol challenge with this antigen by the method of Underwood *et al*,  
32  
33 and Santing *et al*, (Santing *et al*. 1992; Underwood *et al*. 1993). Briefly, each animal was  
34  
35 sensitized by intramuscular injections of 0.35 ml of a 5% (W/V) ovalbumin (OA)/saline  
36  
37 solution into each thigh on days 1 and 4 of each study. On day 25, the animals were  
38  
39 challenged with ovalbumin aerosol in a specially designed animal cage, in which the  
40  
41 guinea pigs may move freely. Habituation of each animal to the cage environment was  
42  
43 initiated 2 days before exposure to OA. Challenge with the allergen was performed by  
44  
45 inhalation of increasing aerosol concentrations containing 1.0, 3.0, 5.0 and 7.0 mg/ml  
46  
47 ovalbumin in saline for 3 min, separated by 7-min intervals. Only those animals  
48  
49 displaying prominent asthmatic symptoms were selected for further evaluation. These  
50  
51 included: i. obvious wheezing, ii. copious nasal discharge of clear, viscous fluid. Average  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 magnitude of disease indicators in animals in groups receiving ASX, EGb761, vitamin C  
4 and combinations thereof, then was measured as described below compared with  
5  
6 treatment groups receiving 10-1,000 mg/kg ibuprofen per day.  
7  
8  
9

10  
11  
12  
13 *Evaluation of lung inflammatory cells:*  
14

15 Animal sacrifice and collection of biological samples was conducted according to  
16 the methods described in Underwood *et al* (Underwood et al. 1993). Briefly, twenty-four  
17 hours after aerosol OA challenge (day 26 of each study), guinea pigs were sacrificed by  
18 decapitation conducted rapidly to minimize pain and discomfort (a departure from the  
19 method used by Underwood *et al*, who used cervical dislocation (Underwood et al. 1993).  
20 Within a timeframe of no more than 8 seconds so as to prevent contamination of the  
21 lungs with peripheral blood, the chest was opened, trachea severed directly above the  
22 bronchi and lungs were removed and lavaged with 50 ml of DulBecco's phosphate-  
23 buffered saline (aliquots of 10 ml), which were aspirated after gentle massage of the  
24 organ. Bronchoalveolar lavage (BAL) fluid was collected and centrifuged at 2200 rpm  
25 (1100 x g) for 10 min, supernatant was aspirated, and pellets were resuspended in 5 ml  
26 0.25% NaCl to lyse residual erythrocytes. This dispersion was centrifuged at 2200 rpm  
27 (1100 x g) for 10 min, supernatant was aspirated, and pellets were resuspended 5 ml 0.9%  
28 NaCl. Total cell counts were done by hemocytometry using trypan blue stain. Slides were  
29 prepared on a Shandon Cytospin 2 (Pittsburgh, PA) at 300 rpm for 5 min, fixed and  
30 stained. Differential cell counts were performed using standard morphologic criteria to  
31 classify cells as eosinophils, neutrophils, or macrophages, and the results were expressed  
32 in cell numbers.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 *Measurement of cAMP and cGMP:*  
7

8 Biopsies from lung tissues were harvested for measurement of cyclic nucleotide  
9 content. cAMP and cGMP were measured using commercially available  
10 radioimmunoassay kits (Amersham). Immediately after sampling, lung biopsies were  
11 frozen by means of a Wollenberger clamp pre-chilled in liquid nitrogen. Samples were  
12 powdered with a pestle and mortar in liquid nitrogen and trichloroacetic acid (TCA) was  
13 added to the powdered frozen samples (10 ml to every mg of tissue). Samples were  
14 further homogenized in frozen TCA using a drying mortar and then centrifuged at 14,000  
15 x g for 10 min at 4°C. The supernatants were extracted 6 times in water-saturated diethyl  
16 ether, evaporated and assayed for cAMP and cGMP by radioimmunoassay using liquid  
17 scintillation counter (Packard, Tri-Carb 2100TR).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 *Dosage selection for drug combination studies:*  
35

36 After evaluating the changes mediated by each drug independently on BAL  
37 inflammatory cells and lung tissue cAMP and cGMP content, the effect of drug co-  
38 administration on these parameters was measured. As shown in Table 1 and Figures 1-5,  
39 three different combinations of astaxanthin, ginkgo extract and vitamin C were used to  
40 estimate the minimum dosage of each agent necessary to maximally suppress each  
41 disease-associated parameter. The dose ranges used in these studies (shown in Table 1  
42 and Figures 1-5) was in excess of what would reasonably be expected to correspond to  
43 veterinary clinical use; and would correspond to unrealistically high dosages if scaled  
44 linearly to the average weight of a human (Feldman and McMahon 1983). However,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 small animals with high metabolic rates typically metabolize a drug much more rapidly  
4  
5 than larger animals; hence the effects seen at the dosages used in this study are expected  
6  
7 to be reasonable predictors of the responses in humans (Feldman and McMahon 1983). In  
8  
9 planning these experiments it was also anticipated that response trends of disease  
10  
11 indicators that may be difficult to detect at lower dosage (but are nonetheless of potential  
12  
13 therapeutic significance), are better-defined at the dosages used here (Feldman and  
14  
15 McMahon 1983).  
16  
17  
18  
19  
20  
21

#### 22 Statistics:

23  
24 The data were expressed as the mean  $\pm$  SEM. One-way analysis of variance test was  
25  
26 first carried out to test for any differences between the mean values of all groups. If  
27  
28 differences were established, the values of the treated groups were compared with those of  
29  
30 the drug-free control group by multiple t-test followed by Bonferroni correction. A change  
31  
32 of  $p < 0.05$  between the drug-free control and treated groups was considered to be significant.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

No unexpected deaths or other adverse effects occurred during the preconditioning period. This was somewhat surprising in the case of animals administered ibuprofen since there is toxicity associated with its chronic use (Bjarnason 2007; Moore 2007) and doses administered were high. It is likely that the animals administered this drug suffered some degree of gastrointestinal damage, however an assessment for this was not made and none of the ibuprofen-treated animals exhibited obvious adverse effects.

Following preconditioning, the 5 inflammation-associated indicators of asthma severity described above in Methods were evaluated in the treated animals and compared with outcomes in two control groups: non asthmatic guinea pigs; and a group of OA-challenged asthmatic animals that had received no drug pre-treatment. As shown in Table 1 and Figures 1-5, significant inhibition of disease indicators was observed in animals administered each product independently and in combination. Comparison of the average magnitude of indicators in treated animal groups with the untreated asthmatic group demonstrated significantly favorable effects ( $p < 0.05$ ) of all products and their combinations in the upper dosage range tested. The indicators: levels of BAL inflammatory cell infiltrate and lung tissue cyclic nucleotide content exhibited significantly favorable dose-responsive correlation to pre-treatment of animals with ASX (Table 1A); *Ginkgo biloba* leaf extract (Table 1B); vitamin C (Table 1C); combined administration of ASX, Ginkgo and vitamin C (Table 1D); and ibuprofen (Table 1E). As shown in Figures 1-5, when compared with drug-free asthmatic controls, animals pretreated with each agent or their combinations showed significant suppression of the

1  
2  
3 disease severity indicators: BAL fluid inflammatory cell content (Figures 1-3); and lung  
4  
5 tissue cyclic nucleotides (Figures 4 and 5) ( $p < 0.05$ ). Treatment of animals with ASX,  
6  
7 Ginkgo and vitamin C or their combinations resulted in suppression of each disease  
8  
9 indicator to the same range as ibuprofen (Table 1, Figures 1-5), demonstrating that under  
10  
11 the conditions of the present study, the three natural products (ASX, Ginkgo and vitamin  
12  
13 C) mediated an anti-inflammatory effect equal or superior to that of ibuprofen.  
14  
15

16  
17 Summative enhancement of drug effects between ASX, EGb761 and vitamin C  
18  
19 was observed (Table 1) but was not an easily identified feature of the experimental  
20  
21 outcomes. Figures 1-5 show average magnitudes of disease indicators in treatment groups  
22  
23 administered the lowest dose of each agent or combination of agents significantly  
24  
25 different ( $p < 0.05$ ) from the untreated asthmatic control group. At the dosages used,  
26  
27 average disease indicator levels in animals receiving combined treatments do not appear  
28  
29 obviously improved versus groups treated with single agents (Figures 1-5). Indeed,  
30  
31 qualitative comparison of inflammatory cell infiltrate numbers between treatment groups  
32  
33 shown in Figures 1-3 suggest that some of the single-agent treated groups experienced  
34  
35 better improvement than those treated with 10 mg/kg each of and EGb761 plus 200  
36  
37 mg/kg of vitamin C. Statistical analysis did however reveal significant additive  
38  
39 interaction between these three agents suggesting benefits to co-administration in  
40  
41 prevention or treatment of asthma. Animals receiving 10 mg/kg ASX (Table 1A), or 10  
42  
43 mg/kg EGb761 (Table 1B), or 200 mg/kg vitamin C (Table 1C), or less independently of  
44  
45 treatment with other agents did not exhibit BAL inflammatory cell numbers or lung tissue  
46  
47 cyclic nucleotide levels significantly different from asthmatic controls. However,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 combined administration of these agents at the dosages stated, correlated with significant  
4  
5 improvement in all disease indicators ( $p < 0.05$ ) (Table 1D).  
6  
7  
8  
9

## 10 **DISCUSSION**

11  
12 The present study demonstrates that in comparison with untreated controls,  
13 animals fed astaxanthin, *Ginkgo biloba* extract and vitamin C alone or in combination  
14 exhibited significantly lower BAL fluid inflammatory cell numbers and enhancement of  
15 lung tissue content of cAMP and cGMP (Figures 1-5). The magnitude of these anti-  
16 inflammatory effects mediated by each phytonutrient product independently was  
17 observed to be in the same range as outcomes in ibuprofen-treated animal groups  
18 (Figures 1-5).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 The data suggest that the anti-inflammatory effects of ASX, EGb761 and  
30 vitamin C acting in concert counteracts pathological inflammation to a more significant  
31 degree than any component acting independently (Table 1). Although summative  
32 enhancement of drug effects was not a striking characteristic of the experimental  
33 outcomes, the significantly reduced dosage of each agent needed to achieve therapeutic  
34 effects when co-administered is clinically meaningful since products for human use in  
35 place of, or augmenting ibuprofen may be configured to contain lower dosage of each  
36 agent, thereby reducing risk of adverse reaction to persons who may be sensitive to any  
37 of the three agents.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 The independent effect of ASX, EGb761, vitamin C and ibuprofen on selected  
51 disease indicators was expected based on the known mechanisms of inflammation  
52 underlying the pathogenesis of asthma and the pharmacology of each of the products. The  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 highly potent free radical scavenging properties of ASX is expected to systemically  
4  
5 suppress the intensity of oxidative processes in ASX-treated animals. Such a shift,  
6  
7 particularly when it occurs in the lungs is observed to activate antioxidant/reactive  
8  
9 oxygen signaling processes that favorably alter major indicators of asthma and related  
10  
11 respiratory syndromes (Fan et al. 1998; Kirkham and Rahman 2006; Kurashige et al.  
12  
13 1990).  
14  
15

16  
17 The experimental endpoints chosen for this study were selected on the basis of  
18  
19 their relevance to asthma-associated inflammation, which is a complex process involving  
20  
21 activation of cytokine networks tissue damage and many other pathological features.  
22  
23 Nevertheless BAL content of inflammatory cells and lung tissue cyclic nucleotide levels  
24  
25 are established indicators of the severity of inflammatory lung disease (Busse 1998; Hai  
26  
27 2007; Hamad et al. 2003; Underwood et al. 1993; Wenzel 1996) and changes in the  
28  
29 magnitude of these indicators provide a simple and direct picture of the effectiveness of a  
30  
31 particular therapy.  
32  
33  
34  
35

36  
37 The ability of EGb761 to mediate the same favorable changes in major disease  
38  
39 indicators as ASX is most likely due primarily to components of the mixture that block  
40  
41 the PAF receptor, principally the terpene trilactones such as ginkgolide B (GB) (Bagnis et  
42  
43 al. 1996; Brochet et al. 1999). Systemic inhibition of PAF-dependent processes is  
44  
45 expected to interrupt the pathogenesis of asthma at several checkpoints. Of particular  
46  
47 importance is the probable effect on pathogenic T lymphocytes that act as triggers for the  
48  
49 disease. These cells express high levels of IL-5 which act in an autocrine and paracrine  
50  
51 manner to induce expression of PAF and its cognate receptor on T cells, inflammatory  
52  
53 cells and several other categories of tissue involved in asthmatic inflammation  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (Calabresse et al. 1992). PAF thus acts as an amplifier of a wide range of inflammation-  
4 associated processes (Calabresse et al. 1992), hence blockade of its receptor is expected  
5 to significantly attenuate the two major indicators of disease studied here, and a host of  
6 others. Other components of EGb761 undoubtedly also contributed to the observed  
7 effects. *Ginkgo biloba* leaf extract, contains bioflavones which inhibit COX-2 and  
8 cAMP-phosphodiesterase (Saponara and Bosisio 1998), the latter property possibly  
9 acting as a contributor to EGb761's ability to enhance cyclic nucleotide levels in lung  
10 tissue. Here cAMP and cGMP content of lung tissue were evaluated as asthma-associated  
11 biomarkers, reflecting efficacy of drug treatments. This is a consequence of the role of  
12 both cAMP and cGMP as second messengers in airway smooth muscle cells (SMC) that  
13 act to decrease contractility thus relaxing the airways and contributing to lessening of  
14 disease severity (Hai 2007; Hamad et al. 2003; Underwood et al. 1993). It is therefore  
15 likely that phosphodiesterase inhibitors present in EGb761 contributed to anti-  
16 inflammatory effects by preservation or enhancement of SMC cyclic nucleotide levels.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Vitamin C was included in our formulations as a water-soluble dietary  
37 antioxidant, expected to act as a physiologic relay, allowing scavenging and urinary  
38 elimination of reactive oxygen metabolites. It has been shown to augment the activity of  
39 astaxanthin in suppression of oxidative damage secondary to *helicobacter pylori* infection  
40 (Wang, Willen, and Wadstrom 2000), a result which suggested it would interact well with  
41 ginkgolides and astaxanthin in suppression of asthma-associated inflammation.  
42  
43  
44  
45  
46  
47  
48  
49

50 The decision to use ibuprofen as a reference drug against which to compare the  
51 anti-inflammatory capacities of the other agents was made with some reservation. Its  
52 therapeutic properties are due substantially to its ability to strongly inhibit COX-2.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 However, the compound also inhibits COX-1, a feature which contributes to dysregulated  
4 platelet aggregation and gastric damage (Kakuta et al. 2008; Rao and Knaus 2008). COX-  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 inhibition additionally promotes bronchoconstriction in asthmatics (Harrington et al. 2008), thereby contributing to lung inflammation and potentially adding a built-in confounder to the study given the use of an asthma model. Rofecoxib (brand name Vioxx) was also considered for use as a reference drug, since as a strongly anti-inflammatory, specific inhibitor of COX-2, with no associated effect on COX-1 (Kose et al. 2009) it was expected to favorably alter asthma inflammation-associated indicators without counteracting these outcomes through exacerbation of the disease process. Two other COX-2 selective NSAIDs, celecoxib (brand name Celebrex) and valdecoxib (brand name Bextra) were also considered for use in the study.

Although Vioxx, Celebrex, Bextra or other COX-2-selective NSAIDs would have been more appropriate to our model, using any of these as a reference drug would not have been consistent with the major aim of this research, which is to compare the anti-inflammatory capacity of phytochemical formulations that may be consumed regularly for general health, with a widely used NSAID that can be taken only for brief periods as a therapeutic measure. The three aforementioned drugs are associated with occurrence of serious, potentially lethal side effects (Chan et al. 2009; Dajani and Islam 2008; El et al. 2009; Ray 2009) and only Celebrex remains in clinical use, making them irrelevant to the aims of this study due to their very limited use in healthcare. Anti-asthmatic drugs were likewise not considered for the present investigation since the objective was not to develop an asthma-specific therapy, but establish groundwork for a phytochemical-based NSAID with clinical application in multiple disorders.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Ultimately it was decided that the advantages of ibuprofen outweighed its drawbacks. The drug is available without prescription, is one of the most widely-used anti-inflammatory compounds ever manufactured and in 2005 was designated by the World Health Organization (WHO) as an essential public health resource for all nations (*WHO Model List of Essential Medicines. World Health Organization. 2005*). Moreover, despite its potential to exacerbate bronchoconstriction, it has known clinical utility in preventing asthma-associated morbidity in children (Mazur 2002), raising the possibility that use of ibuprofen as a reference for these studies might yield new insight into the ability of the drug to complement existing strategies for management of asthma.

#### CONCLUSIONS:

Results of the present study suggest that a product based on the combined activity of ASX, EGb761 and vitamin C would be of substantial benefit for a large percentage of the World's population at risk of or suffering from chronic inflammatory disease. The product would be as potent as ibuprofen, but could be consumed prophylactically for general health to decrease the overall risk of chronic inflammatory disease; and would also be valuable for augmenting the effects of other therapies for persons who become ill.

ASX and ginkgo extracts are minimally toxic (Bagnis et al. 1996; Haines et al. 2000; Mahmoud et al. 2002; Mahmoud et al. 2004; Wang, Willen, and Wadstrom 2000) and are marketed in the U.S. without prescription as components of food or food supplements. The present study demonstrates that oral administration of these phytonutrients to asthmatic animals along with vitamin C, significantly improved major indicators of asthma severity. Specifically, the therapeutic agents reduced lung infiltration

1  
2  
3 by polymorphonuclear leukocytes; and increased levels of cyclic nucleotides in lung  
4  
5 tissue. Both effects correlate strongly with reduced inflammation and improved prognosis  
6  
7 in asthma (Busse 1998; Hai 2007; Hamad et al. 2003; Wenzel 1996). These observations  
8  
9 suggest that the phytochemical formulations evaluated here, have potential to decrease  
10  
11 risk of, and improve therapy for a diverse spectrum of inflammatory pathologies and  
12  
13 could greatly improve quality-of-life for millions of people Worldwide.  
14  
15  
16  
17  
18  
19

### 20 **ACKNOWLEDGMENT**

21  
22 The authors acknowledge the efforts of Stephanie C. Fox, President, QueenBeeEdit in  
23  
24 formatting proofreading and editing this manuscript in preparation for publication. This  
25  
26 study was supported by grants from OTKA 72315, OTKA 78223, GVOP-3.2.1.-2004-04-  
27  
28 0269/3.0, TAMOP-4.2.2-08/1-2008-0007, and TAMOP-4.2.1.B-09/1.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**REFERENCES**

Asako H, Kubes P, Baethge BA, Wolf RE, and Granger DN. 1992. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. *Transplantation* **54**: 686-90.

Bagnis C, Deray G, Dubois M, Pirotzky E, Jacquiaud C, Baghos W, Aupetit B, Braquet P, and Jacobs C. 1996. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. *Nephrol Dial Transplant* **11**: 507-13.

Bjarnason I. 2007. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. *J R Soc Med* **100 Suppl 48**: 11-4.

Brochet D, Chermat R, DeFeudis FV, and Drieu K. 1999. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. *Gen Pharmacol* **33**: 249-56.

Busse WW. 1998. Leukotrienes and inflammation. *Am J Respir Crit Care Med* **157**: S210-3; discussion S247-8.

Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard Y, and Thomas Y. 1992. Induction of high-affinity paf receptor expression during T cell activation. *Eur J Immunol* **22**: 1349-55.

- 1  
2  
3 Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, and Krum H. 2009. Do COX-2 inhibitors  
4 raise blood pressure more than nonselective NSAIDs and placebo? An updated  
5 meta-analysis. *J Hypertens* **27**: 2332-41.  
6  
7  
8  
9  
10  
11 Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, and Simmons  
12 DL. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and  
13 other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl*  
14 *Acad Sci U S A* **99**: 13926-31.  
15  
16  
17  
18  
19  
20  
21  
22 Dajani EZ, and Islam K. 2008. Cardiovascular and gastrointestinal toxicity of selective  
23 cyclo-oxygenase-2 inhibitors in man. *J Physiol Pharmacol* **59 Suppl 2**: 117-33.  
24  
25  
26  
27  
28 El H, II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, and Kandil HM. 2009.  
29 Celecoxib-induced cholestatic liver failure requiring orthotopic liver  
30 transplantation. *World J Gastroenterol* **15**: 3937-9.  
31  
32  
33  
34  
35  
36  
37 Evans EG. 2003. Drug synergies and the potential for combination therapy in  
38 onychomycosis. *Br J Dermatol* **149 Suppl 65**: 11-3.  
39  
40  
41  
42  
43 Fan L, Vonshak A, Zarka A, and Boussiba S. 1998. Does astaxanthin protect  
44 Haematococcus against light damage? *Z Naturforsch C* **53**: 93-100.  
45  
46  
47  
48  
49 Feldman HA, and McMahon TA. 1983. The 3/4 mass exponent for energy metabolism is  
50 not a statistical artifact. *Respir Physiol* **52**: 149-63.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Grosser T. 2009. Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. *J Investig Med* **57**: 709-16.

Hai CM. 2007. Airway smooth muscle cell as therapeutic target of inflammation. *Curr Med Chem* **14**: 67-76.

Haines DD, Bak I, Ferdinandy P, Mahmoud FF, Al-Harbi SA, Blasig IE, and Tosaki A. 2000. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. *J Cardiovasc Pharmacol* **35**: 37-44.

Hamad AM, Clayton A, Islam B, and Knox AJ. 2003. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. *Am J Physiol Lung Cell Mol Physiol* **285**: L973-83.

Harrington LS, Lucas R, McMaster SK, Moreno L, Scadding G, Warner TD, and Mitchell JA. 2008. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. *FASEB J* **22**: 4005-10.

Hawkey CJ. 2001. COX-1 and COX-2 inhibitors. *Best Pract Res Clin Gastroenterol* **15**: 801-20.

Kakuta H, Zheng X, Oda H, Harada S, Sugimoto Y, Sasaki K, and Tai A. 2008. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that



1  
2  
3 do not cause gastric damage. design and in vitro/in vivo evaluation of a  
4  
5 benzamide-type cyclooxygenase-1 selective inhibitor. *J Med Chem* **51**: 2400-11.  
6  
7

8  
9 Kang JO, Kim SJ, and Kim H. 2001. Effect of astaxanthin on the hepatotoxicity, lipid  
10 peroxidation and antioxidative enzymes in the liver of CCl<sub>4</sub>-treated rats. *Methods*  
11  
12 *Find Exp Clin Pharmacol* **23**: 79-84.  
13  
14

15  
16  
17 Kirkham P, and Rahman I. 2006. Oxidative stress in asthma and COPD: antioxidants as a  
18 therapeutic strategy. *Pharmacol Ther* **111**: 476-94.  
19  
20

21  
22  
23 Kose F, Besen A, Paydas S, Balal M, Gonlusen G, Inal T, Dogan A, and Kibar M. 2009.  
24 Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with  
25 furosemide on renal functions and renal Cox-2 expression in rats. *Clin Exp*  
26  
27 *Nephrol*.  
28  
29  
30  
31

32  
33  
34 Kurashige M, Okimasu E, Inoue M, and Utsumi K. 1990. Inhibition of oxidative injury of  
35 biological membranes by astaxanthin. *Physiol Chem Phys Med NMR* **22**: 27-38.  
36  
37

38  
39  
40 Mahmoud FF, Abul HT, Haines DD, Abal AT, and Wise JA. 2002. In vitro effects of  
41 ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5  
42 expression in peripheral blood mononuclear cells from asthmatic subjects.  
43  
44  
45  
46  
47 *Transplant Proc* **34**: 2958-61.  
48

49  
50 Mahmoud FF, Haines DD, Abul HT, Abal AT, Onadeko BO, and Wise JA. 2004. In vitro  
51 effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 peripheral blood mononuclear cells from asthmatic subjects. *J Pharmacol Sci* **94**:  
4  
5 129-36.  
6  
7

8  
9 Mazur LJ. 2002. Ibuprofen was more protective against asthma morbidity than  
10  
11 acetaminophen in asthmatic children with fever. *ACP J Club* **137**: 108.  
12  
13

14  
15 Moore N. 2007. Ibuprofen: a journey from prescription to over-the-counter use. *J R Soc*  
16  
17 *Med* **100 Suppl 48**: 2-6.  
18  
19

20  
21 Rao P, and Knaus EE. 2008. Evolution of nonsteroidal anti-inflammatory drugs  
22  
23 (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *J Pharm Pharm Sci* **11**:  
24  
25 81s-110s.  
26  
27

28  
29 Ray A. 2009. Beyond debacle and debate: developing solutions in drug safety. *Nat Rev*  
30  
31 *Drug Discov* **8**: 775-9.  
32  
33

34  
35 Santing RE, Meurs H, van der Mark TW, Remie R, Oosterom WC, Brouwer F, and  
36  
37 Zaagsma J. 1992. A novel method to assess airway function parameters in  
38  
39 chronically instrumented, unrestrained guinea-pigs. *Pulm Pharmacol* **5**: 265-72.  
40  
41

42  
43 Saponara R, and Bosisio E. 1998. Inhibition of cAMP-phosphodiesterase by biflavones of  
44  
45 Ginkgo biloba in rat adipose tissue. *J Nat Prod* **61**: 1386-7.  
46  
47

48  
49 Sasakawa Y, Sakuma S, Higashi Y, Sasakawa T, Amaya T, and Goto T. 2000. FK506  
50  
51 suppresses neutrophil chemoattractant production by peripheral blood  
52  
53 mononuclear cells. *Eur J Pharmacol* **403**: 281-8.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Soberman RJ, and Christmas P. 2003. The organization and consequences of eicosanoid  
4  
5 signaling. *J Clin Invest* **111**: 1107-13.  
6  
7  
8  
9 Umetsu DT, McIntire JJ, Akbari O, Macaubas C, and DeKruyff RH. 2002. Asthma: an  
10  
11 epidemic of dysregulated immunity. *Nat Immunol* **3**: 715-20.  
12  
13  
14  
15 Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Udem BJ, Hand  
16  
17 JM, and Torphy TJ. 1993. Inhibition of antigen-induced bronchoconstriction and  
18  
19 eosinophil infiltration in the guinea pig by the cyclic AMP-specific  
20  
21 phosphodiesterase inhibitor, rolipram. *J Pharmacol Exp Ther* **266**: 306-13.  
22  
23  
24  
25  
26 Wallace JL. 1999. Distribution and expression of cyclooxygenase (COX) isoenzymes,  
27  
28 their physiological roles, and the categorization of nonsteroidal anti-inflammatory  
29  
30 drugs (NSAIDs). *Am J Med* **107**: 11S-16S; discussion 16S-17S.  
31  
32  
33  
34 Wang X, Willen R, and Wadstrom T. 2000. Astaxanthin-rich algal meal and vitamin C  
35  
36 inhibit *Helicobacter pylori* infection in BALB/cA mice. *Antimicrob Agents*  
37  
38 *Chemother* **44**: 2452-7.  
39  
40  
41  
42 Warner TD, and Mitchell JA. 2002. Cyclooxygenase-3 (COX-3): filling in the gaps  
43  
44 toward a COX continuum? *Proc Natl Acad Sci U S A* **99**: 13371-3.  
45  
46  
47  
48 Wenzel-Seifert K, and Seifert R. 1993. Partial inhibition of human neutrophil activation  
49  
50 by FK-506 at supratherapeutic concentrations. *Naunyn Schmiedebergs Arch*  
51  
52 *Pharmacol* **348**: 7-13.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Wenzel SE. 1996. Abnormalities of cell and mediator levels in bronchoalveolar lavage  
4 fluid of patients with mild asthma. *J Allergy Clin Immunol* **98**: S17-21; discussion  
5 S33-40.  
6  
7  
8  
9

10  
11 *WHO Model List of Essential Medicines. World Health Organization. 2005 [cited.*  
12  
13 Available from [http://whqlibdoc.who.int/hq/2005/a87017\\_eng.pdf](http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf)  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

1  
2  
3 **Figure 1. Magnitude of inflammation-associated responses in animals treated with**  
4 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**  
5 **eosinophils.**

6  
7 OA-sensitized Guinea pig groups (6 animals in each group) treated as described  
8 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract  
9 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C  
10 and 0-1,000 mg/kg ibuprofen (IBP). Data shown are restricted to outcomes from  
11 treatment groups receiving the lowest dose of each product resulting in values of each  
12 inflammation indicator significantly different ( $p < 0.05$ ) than results from asthmatic, drug-  
13 free control animals.  
14

15  
16 \* Inflammation indicator magnitudes significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free  
17 control animals.  
18

19  
20 **Figure 2. Magnitude of inflammation-associated responses in animals treated with**  
21 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**  
22 **neutrophils.**

23  
24 OA-sensitized Guinea pig groups (6 animals in each group) treated as described  
25 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract  
26 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C  
27 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment  
28 groups receiving the lowest dose of each product resulting in values of each inflammation  
29 indicator significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free control  
30 animals.  
31

32  
33 \* Inflammation indicator magnitudes significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free  
34 control animals.  
35

36 **Figure 3. Magnitude of inflammation-associated responses in animals treated with**  
37 **phytonutrients or ibuprofen: Bronchoalveolar lavage (BAL) fluid content of**  
38 **macrophages.**

39  
40 OA-sensitized Guinea pig groups (6 animals in each group) treated as described  
41 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract  
42 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C  
43 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment  
44 groups receiving the lowest dose of each product resulting in values of each inflammation  
45 indicator significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free control  
46 animals.  
47

48  
49 \* Inflammation indicator magnitudes significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free  
50 control animals.  
51

52 **Figure 4. Magnitude of inflammation-associated responses in animals treated with**  
53 **phytonutrients or ibuprofen: enhanced lung tissue content of cAMP.**

54  
55 OA-sensitized Guinea pig groups (6 animals in each group) treated as described  
56 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract  
57 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C  
58  
59  
60

1  
2  
3 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment  
4 groups receiving the lowest dose of each product resulting in values of each inflammation  
5 indicator significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free control  
6 animals.  
7

8  
9 \* Inflammation indicator magnitudes significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free  
10 control animals.  
11

12  
13 **Figure 5. Magnitude of inflammation-associated responses in animals treated with  
14 phytonutrients or ibuprofen: enhanced lung tissue content of cGMP.**

15 OA-sensitized Guinea pig groups (6 animals in each group) treated as described  
16 previously with 0-200 mg/kg astaxanthin (ASX), 0-100 mg/kg *Ginkgo biloba* leaf extract  
17 (EGb761), 0-400 mg/kg vitamin C (VitC), combinations of ASX, Ginkgo and vitamin C  
18 and 0-1,000 mg/kg ibuprofen (IBP). Data shown is restricted to outcomes from treatment  
19 groups receiving the lowest dose of each product resulting in values of each inflammation  
20 indicator significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free control  
21 animals.  
22

23  
24 \* Inflammation indicator magnitudes significantly different ( $p < 0.05$ ) than results from asthmatic, drug-free  
25 control animals.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1.  
Bronchoalveolar lavage (BAL) eosinophil content




Figure 2.  
Bronchoalveolar lavage (BAL) Neutrophil content






Figure 3.  
Bronchoalveolar lavage (BAL) macrophage content




Figure 4.  
Lung Tissue cAMP content





Figure 5.  
Lung Tissue cGMP content



**Table 1. Lung inflammation-associated parameter values in treatment groups (basic data).**

Numbers of inflammatory cells in bronchoalveolar lavage (BAL) fluid and levels of the cyclic nucleotides cAMP and cGMP in lung tissue were measured in ovalbumin (OA)-sensitized guinea pigs, segregated into dosage groups of 6 animals each and administered feed containing the following supplements (referred to here as “drugs): astaxanthin (1A), *Ginkgo biloba* leaf extract (EGb761) (1B), vitamin C (1C), selected combinations of each (1D), or ibuprofen (1E), daily for 26 days. Two groups, designated as drug-free controls were given feed without phytochemicals or ibuprofen. One of these two control groups was exposed to vehicle aerosol (nebulized saline) only, without OA challenge and is designated below: “OA-neg, non-asthma, no drugs”. The other control group which received an OA challenge is designated below: “OA+ asthma+, no drugs”. Twentyfour hours following the 26-day drug treatment period, asthma was induced by OA inhalation, animals were sacrificed and BAL inflammatory cell levels and lung tissue cyclic nucleotide content was measured in each animal. Data is reported as mean  $\pm$  standard error of means (SEM) of measurements taken in the 6 animals constituting each treatment group.

**1A. Astaxanthin (ASX)-treated animals.**

Cohort size: n = 6	OA-neg non-asthma no drugs	OA+ asthma+ no drugs	OA+ 5mg/kg ASX	OA+ 10mg/kg ASX	OA+ 30mg/kg ASX	OA+ 100mg/kg ASX	OA+ 200mg/kg ASX
Eosinophils (cells x 10 <sup>6</sup> /animal).	1.4 $\pm$ 0.2	5.4 $\pm$ 0.8	5.0 $\pm$ 0.7	4.6 $\pm$ 0.6	3.1 $\pm$ 0.5*	2.4 $\pm$ 0.6*	2.3 $\pm$ 0.5*
Neutrophils (cells x 10 <sup>5</sup> /animal)	1.1 $\pm$ 0.3	5.8 $\pm$ 0.7	5.4 $\pm$ 0.8	5.1 $\pm$ 0.6	3.3 $\pm$ 0.8*	2.4 $\pm$ 0.5*	2.0 $\pm$ 0.4*
Macrophages (cells x 10 <sup>6</sup> /animal)	1.7 $\pm$ 0.5	9.9 $\pm$ 1.1	9.6 $\pm$ 1.0	8.0 $\pm$ 0.8	3.7 $\pm$ 0.7*	2.70 $\pm$ 0.7*	2.6 $\pm$ 0.5*
cAMP pMol/mg lung protein	10.9 $\pm$ 0.98	6.7 $\pm$ 0.58	6.9 $\pm$ 0.5	8.1 $\pm$ 0.8	9.6 $\pm$ 0.8*	12.6 $\pm$ 0.8*	12.1 $\pm$ 0.5*
cGMP pMol/mg lung protein	2.6 $\pm$ 0.26	1.1 $\pm$ 0.17	1.2 $\pm$ 0.1	1.4 $\pm$ 0.1	1.8 $\pm$ 0.3*	2.8 $\pm$ 0.3*	2.7 $\pm$ 0.2*

**1B. *Ginkgo biloba* (EGb761)-treated animals.**

Cohort size: n = 6	OA-neg non- asthma no drugs	OA+ asthma+ no drugs	OA+ 5mg/kg EGb761	OA+ 10mg/kg EGb761	OA+ 30mg/kg EGb761	OA+ 100mg/kg EGb761
Eosinophils (cells x 10 <sup>6</sup> /animal).	1.4 $\pm$ 0.2	5.4 $\pm$ 0.8	5.1 $\pm$ 0.9	5.0 $\pm$ 0.8	3.5 $\pm$ 0.8*	3.1 $\pm$ 0.5*
Neutrophils (cells x 10 <sup>5</sup> /animal)	1.1 $\pm$ 0.3	5.8 $\pm$ 0.7	5.6 $\pm$ 0.6	5.4 $\pm$ 0.6	3.5 $\pm$ 0.7*	3.3 $\pm$ 0.6*
Macrophages (cells x 10 <sup>6</sup> /animal)	1.7 $\pm$ 0.5	9.9 $\pm$ 1.1	9.8 $\pm$ 1.1	9.4 $\pm$ 1.1	4.9 $\pm$ 1.5*	4.2 $\pm$ 0.6*
cAMP pMol/mg lung protein	10.9 $\pm$ 0.98	6.7 $\pm$ 0.58	6.9 $\pm$ 0.6	8.0 $\pm$ 0.9	9.8 $\pm$ 0.7*	12.0 $\pm$ 1.3*
cGMP pMol/mg lung protein	2.6 $\pm$ 0.26	1.1 $\pm$ 0.17	1.1 $\pm$ 0.2	1.1 $\pm$ 0.2	1.5 $\pm$ 0.2*	1.8 $\pm$ 0.3*

## 1C. Vitamin C-treated animals.

Cohort size: n = 6	OA-neg non- asthma no drugs	OA+ asthma+ no drug	OA+ 50mg/kg Vit. C	OA+ 100mg/kg Vit. C	OA+ 200mg/kg Vit. C	OA+ 400mg/kg Vit. C
Eosinophils (cells x 10 <sup>6</sup> /animal).	1.4±0.2	5.4±0.8	5.5±0.5	5.5±0.8	4.8±1.1	3.5±0.9*
Neutrophils (cells x 10 <sup>5</sup> /animal)	1.1±0.3	5.8±0.7	5.4±0.6	5.6±0.8	5.0±0.8	4.7±0.9
Macrophages (cells x 10 <sup>6</sup> /animal)	1.7±0.5	9.9±1.1	9.5±0.9	9.8±0.9	9.2 ±0.8	7.2±1.5*
cAMP pMol/mg lung protein	10.9±0.98	6.7±0.58	6.8±0.5	7.1±0.8	7.9±0.9	7.9±0.8
cGMP pMol/mg lung protein	2.6±0.26	1.1±0.17	1.1±0.2	1.0±0.2	1.2±0.2	1.5±0.2*

1D. Combination treatments: Animals simultaneously administered astaxanthin, *Ginkgo biloba* (EGb761) and vitamin C

Cohort size: n = 6	OA-neg non- asthma no drugs	OA+ asthma+ no drug	OA+ 5 mg/kg ASX + 5 mg/kg EGb761 + 50 mg/kg Vit C	OA+ 10 mg/kg ASX + 10 mg/kg EGb761 + 200 mg/kg Vit C	OA+ 30 mg/kg ASX + 30 mg/kg EGb761 + 400 mg/kg Vit C
Eosinophils (cells x 10 <sup>6</sup> /animal).	1.4±0.2	5.4±0.8	5.07±0.63	3.44±0.84*	2.95±0.62*
Neutrophils (cells x 10 <sup>5</sup> /animal)	1.1±0.3	5.8±0.7	5.27±0.74	3.65±0.65*	2.60±0.69*
Macrophages (cells x 10 <sup>6</sup> /animal)	1.7±0.5	9.9±1.1	9.40±0.96	5.78±1.18*	2.98±0.71*
cAMP pMol/mg lung protein	10.9±0.98	6.7±0.58	7.17± 0.61	9.28±0.94*	13.00±0.76*
cGMP pMol/mg lung protein	2.6±0.26	1.1±0.17	1.17± 0.19	2.09±0.48*	2.84±0.28*

## 1E. Ibuprofen-treated animals.

Cohort size: n = 6	Asthma-free control (OA neg)	OA+ asthma, no drug	OA+ IB 10mg/kg	OA+ IB 100mg/kg	OA+ IB 500mg/kg	OA+ IB 1000mg/kg
Eosinophils (cells x 10 <sup>6</sup> /animal).	1.4±0.2	5.4±0.8	5.4±0.8	4.7±0.6	3.0±0.8*	2.9±0.5*
Neutrophils (cells x 10 <sup>5</sup> /animal)	1.1±0.3	5.8±0.7	5.7±0.7	5.0±0.7	3.1±0.9*	3.1±0.5*
Macrophages (cells x 10 <sup>6</sup> /animal)	1.7±0.5	9.9±1.1	9.5±0.8	9.0±1.3	4.7±1.3*	4.3±0.9*
cAMP pMol/mg lung protein	10.9±0.98	6.7±0.58	7.1±0.6	7.3±0.9	8.2±0.8*	8.1±0.9*
cGMP pMol/mg lung protein	2.6±0.26	1.1±0.17	1.1±0.2	1.1±0.2	1.4±0.2	1.6±0.2*

\*p<0.05 compared to corresponding values of OA antigen-challenged, asthmatic drug-free control group.